Search

Your search keyword '"Malkova, N."' showing total 231 results

Search Constraints

Start Over You searched for: Author "Malkova, N." Remove constraint Author: "Malkova, N."
231 results on '"Malkova, N."'

Search Results

1. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial

3. The Liberal Arts in Russia: A Superfluous Luxury or a Justified Necessity?

4. Interface States in Stressed Semiconductor Heterojunction with Antiferromagnetic Ordering

5. Electron spectrum of magnetic interface structures based on narrow-gap semiconductors

9. Results of a Randomized Open Multicenter Comparative Study of the Tolerability and Safety of Gilenya (fingolimod) in Patients with Remitting Multiple Sclerosis (the GIMN study)

10. Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia

13. Consensus of expert advices on routing, diagnosis, and management of patients with neuromyelitis optica spectrum disorders

14. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

25. Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis

30. ALIMENTARY-FUNCTIONAL DIARRHEA OF CALVES AND ITS THERAPY

32. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis

34. The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis

35. The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis

37. Polymorphic Variants of Immune Response Genes as a Risk Factor for the Development of Primary Progressive Multiple Sclerosis

38. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

39. Phase III Dose-Comparison Study of Glatiramer Acetate for Multiple Sclerosis

41. Primary-progressive multiple sclerosis in Russia: a medical-sociological study involving patients and neurologists

42. Provision of alemtuzumab safety is one of the main components of pharmacovigilance

43. Abstract P3-04-05: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models

44. Polymorphic variants of the immune response genes as risk factors for primary progressive multiple sclerosis

45. Primary progressive multiple sclerosis: current issues of timely diagnosis

46. Clinical recommendations on the use of alemtuzumab (lemtrada)

48. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

49. Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

50. Clinical recommendations on the use of teriflunomide

Catalog

Books, media, physical & digital resources